NCT07443592 2026-03-02
LAL-2025
PETHEMA Foundation
Phase NA Not yet recruiting
Clinical Trials
11 trialsNCT02458014 2025-09-23
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05182385 2025-07-25
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Goethe University
Phase 1/2 Active not recruiting
NCT04827745 2025-07-03
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
University of Maryland, Baltimore
Phase 2 Completed
NCT07003737 2025-06-04
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
First Affiliated Hospital of Zhejiang University
Phase NA Recruiting
NCT06763302 2025-01-08
NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL
The Children's Hospital of Zhejiang University School of Medicine
Phase NA Not yet recruiting
NCT03982992 2024-03-12
DLI-TARGET
Ludwig-Maximilians - University of Munich
Phase 2 Withdrawn
NCT04785547 2024-01-16
ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT
St. Anna Kinderkrebsforschung
Phase 2 Terminated
NCT06125106 2023-11-09
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
Zhejiang University
Phase 1 Unknown
NCT04604691 2022-03-08
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
Seoul National University Hospital
Phase 1 Unknown
NCT04044560 2022-02-21
OZM-097
University of British Columbia
Phase 2 Terminated